Day:

EMA invites feedback to strengthen how the EU generates and uses evidence that reflects what matters to patients, including in rare diseases
Regulatory sandboxes have emerged as an innovative mechanism to facilitate the development and approval of new technologies, including pharmaceuticals. Their application in the context of rare disease therapies presents a promising avenue to accelerate the development, approval, and access to disease-modifying and life-saving therapies. Given the complexities of rare diseases and the regulatory hurdles faced by orphan medicinal products, regulatory sandboxes offer a structured yet flexible environment where new regulatory approaches can be tested and refined.
Accelerating evidence-driven innovation to unlock fresh indications for established therapies.
Complex regional pain syndrome (CRPS) is a rare, disabling pain disorder. Systematic reviews have identified a critical lack of high-quality clinical trial evidence to inform the management of CRPS. There is an urgent need to find solutions to the methodological challenges of undertaking clinical trials in CRPS. The aim of this project was to develop a methodological framework for optimising future clinical trials in CRPS (OptiMeth-CRPS).
Bringing together global experts, healthcare professionals, patient advocates, and policymakers to advance knowledge and strengthen international collaboration in the field of rare diseases.